AUXLY CANNABIS GROUP INC (XLY.CA) Stock Fundamental Analysis
Canada • Toronto Stock Exchange • TSX:XLY • CA05335P1099
0.13 CAD
0 (0%)
Last: Feb 3, 2026, 07:00 PM
We assign a fundamental rating of 6 out of 10 to XLY. XLY was compared to 33 industry peers in the Pharmaceuticals industry. XLY has only an average score on both its financial health and profitability. XLY has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination!
1. Profitability
1.1 Basic Checks
- In the past year XLY was profitable.
- XLY had a positive operating cash flow in the past year.
- XLY had negative earnings in each of the past 5 years.
- In multiple years XLY reported negative operating cash flow during the last 5 years.
1.2 Ratios
- With an excellent Return On Assets value of 16.40%, XLY belongs to the best of the industry, outperforming 96.97% of the companies in the same industry.
- Looking at the Return On Equity, with a value of 26.28%, XLY belongs to the top of the industry, outperforming 96.97% of the companies in the same industry.
- Looking at the Return On Invested Capital, with a value of 8.12%, XLY belongs to the top of the industry, outperforming 90.91% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.4% | ||
| ROE | 26.28% | ||
| ROIC | 8.12% |
ROA(3y)-20.84%
ROA(5y)-18.51%
ROE(3y)-81.82%
ROE(5y)-60.99%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- With an excellent Profit Margin value of 31.05%, XLY belongs to the best of the industry, outperforming 96.97% of the companies in the same industry.
- XLY has a Operating Margin of 17.28%. This is amongst the best in the industry. XLY outperforms 81.82% of its industry peers.
- Looking at the Gross Margin, with a value of 52.00%, XLY is in the better half of the industry, outperforming 78.79% of the companies in the same industry.
- XLY's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 17.28% | ||
| PM (TTM) | 31.05% | ||
| GM | 52% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y29.45%
GM growth 5YN/A
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), XLY is destroying value.
- XLY has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for XLY has been increased compared to 5 years ago.
- The debt/assets ratio for XLY has been reduced compared to a year ago.
2.2 Solvency
- XLY has an Altman-Z score of 0.01. This is a bad value and indicates that XLY is not financially healthy and even has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of 0.01, XLY is in line with its industry, outperforming 57.58% of the companies in the same industry.
- XLY has a debt to FCF ratio of 4.16. This is a neutral value as XLY would need 4.16 years to pay back of all of its debts.
- XLY has a better Debt to FCF ratio (4.16) than 81.82% of its industry peers.
- A Debt/Equity ratio of 0.30 indicates that XLY is not too dependend on debt financing.
- XLY's Debt to Equity ratio of 0.30 is in line compared to the rest of the industry. XLY outperforms 54.55% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.3 | ||
| Debt/FCF | 4.16 | ||
| Altman-Z | 0.01 |
ROIC/WACC1
WACC8.14%
2.3 Liquidity
- XLY has a Current Ratio of 1.93. This is a normal value and indicates that XLY is financially healthy and should not expect problems in meeting its short term obligations.
- XLY has a Current ratio (1.93) which is in line with its industry peers.
- XLY has a Quick Ratio of 1.05. This is a normal value and indicates that XLY is financially healthy and should not expect problems in meeting its short term obligations.
- XLY has a Quick ratio (1.05) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.93 | ||
| Quick Ratio | 1.05 |
3. Growth
3.1 Past
- XLY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 151.10%, which is quite impressive.
- The Revenue has grown by 27.38% in the past year. This is a very strong growth!
- Measured over the past years, XLY shows a very strong growth in Revenue. The Revenue has been growing by 71.07% on average per year.
EPS 1Y (TTM)151.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%433.33%
Revenue 1Y (TTM)27.38%
Revenue growth 3Y13.43%
Revenue growth 5Y71.07%
Sales Q2Q%19.57%
3.2 Future
- XLY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 53.92% yearly.
- The Revenue is expected to grow by 22.57% on average over the next years. This is a very strong growth
EPS Next Y210.75%
EPS Next 2Y53.92%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year14.35%
Revenue Next 2Y10.97%
Revenue Next 3Y26.12%
Revenue Next 5Y22.57%
3.3 Evolution
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 3.25, which indicates a rather cheap valuation of XLY.
- Compared to the rest of the industry, the Price/Earnings ratio of XLY indicates a rather cheap valuation: XLY is cheaper than 93.94% of the companies listed in the same industry.
- The average S&P500 Price/Earnings ratio is at 28.18. XLY is valued rather cheaply when compared to this.
- A Price/Forward Earnings ratio of 12.87 indicates a correct valuation of XLY.
- XLY's Price/Forward Earnings ratio is rather cheap when compared to the industry. XLY is cheaper than 81.82% of the companies in the same industry.
- XLY is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 25.51, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3.25 | ||
| Fwd PE | 12.87 |
4.2 Price Multiples
- 84.85% of the companies in the same industry are more expensive than XLY, based on the Enterprise Value to EBITDA ratio.
- XLY's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. XLY is cheaper than 75.76% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.05 | ||
| EV/EBITDA | 5.86 |
4.3 Compensation for Growth
- XLY's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The decent profitability rating of XLY may justify a higher PE ratio.
- XLY's earnings are expected to grow with 53.92% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.02
PEG (5Y)N/A
EPS Next 2Y53.92%
EPS Next 3YN/A
5. Dividend
5.1 Amount
- No dividends for XLY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
TSX:XLY (2/3/2026, 7:00:00 PM)
0.13
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2025-11-13/bmo
Earnings (Next)03-18 2026-03-18/amc
Inst Owners0.01%
Inst Owner ChangeN/A
Ins Owners5.73%
Ins Owner ChangeN/A
Market Cap175.30M
Revenue(TTM)146.00M
Net Income(TTM)45.34M
Analysts80
Price Target0.26 (100%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1150%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.89%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3.25 | ||
| Fwd PE | 12.87 | ||
| P/S | 1.2 | ||
| P/FCF | 11.05 | ||
| P/OCF | 9.44 | ||
| P/B | 1.02 | ||
| P/tB | 1.22 | ||
| EV/EBITDA | 5.86 |
EPS(TTM)0.04
EY30.77%
EPS(NY)0.01
Fwd EY7.77%
FCF(TTM)0.01
FCFY9.05%
OCF(TTM)0.01
OCFY10.59%
SpS0.11
BVpS0.13
TBVpS0.11
PEG (NY)0.02
PEG (5Y)N/A
Graham Number0.34
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.4% | ||
| ROE | 26.28% | ||
| ROCE | 11.28% | ||
| ROIC | 8.12% | ||
| ROICexc | 9.41% | ||
| ROICexgc | 11.05% | ||
| OM | 17.28% | ||
| PM (TTM) | 31.05% | ||
| GM | 52% | ||
| FCFM | 10.87% |
ROA(3y)-20.84%
ROA(5y)-18.51%
ROE(3y)-81.82%
ROE(5y)-60.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y29.45%
GM growth 5YN/A
F-Score7
Asset Turnover0.53
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.3 | ||
| Debt/FCF | 4.16 | ||
| Debt/EBITDA | 1.42 | ||
| Cap/Depr | 25.18% | ||
| Cap/Sales | 1.85% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 51.64% | ||
| Profit Quality | 34.99% | ||
| Current Ratio | 1.93 | ||
| Quick Ratio | 1.05 | ||
| Altman-Z | 0.01 |
F-Score7
WACC8.14%
ROIC/WACC1
Cap/Depr(3y)27.93%
Cap/Depr(5y)61.49%
Cap/Sales(3y)4.52%
Cap/Sales(5y)11.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)151.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%433.33%
EPS Next Y210.75%
EPS Next 2Y53.92%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)27.38%
Revenue growth 3Y13.43%
Revenue growth 5Y71.07%
Sales Q2Q%19.57%
Revenue Next Year14.35%
Revenue Next 2Y10.97%
Revenue Next 3Y26.12%
Revenue Next 5Y22.57%
EBIT growth 1Y204.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year772.58%
EBIT Next 3Y106.86%
EBIT Next 5Y66%
FCF growth 1Y4857.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y201.87%
OCF growth 3YN/A
OCF growth 5YN/A
AUXLY CANNABIS GROUP INC / XLY.CA FAQ
What is the ChartMill fundamental rating of AUXLY CANNABIS GROUP INC (XLY.CA) stock?
ChartMill assigns a fundamental rating of 6 / 10 to XLY.CA.
Can you provide the valuation status for AUXLY CANNABIS GROUP INC?
ChartMill assigns a valuation rating of 8 / 10 to AUXLY CANNABIS GROUP INC (XLY.CA). This can be considered as Undervalued.
Can you provide the profitability details for AUXLY CANNABIS GROUP INC?
AUXLY CANNABIS GROUP INC (XLY.CA) has a profitability rating of 6 / 10.
Can you provide the financial health for XLY stock?
The financial health rating of AUXLY CANNABIS GROUP INC (XLY.CA) is 4 / 10.